TABLE 1.
Demographic and treatment characteristics of study cohort and randomly selected sub-cohort.
| Characteristic, n (%)* | Cohort n=509 |
Sub-Cohort n=509 |
P- value |
||
|---|---|---|---|---|---|
| Female | 653 | (47.4) | 238 | (46.8) | 0.84 |
| Age at transplant, years | 0.79 | ||||
| <20 | 302 | (21.9) | 110 | (21.6) | |
| 20–39 | 360 | (26.1) | 144 | (28.3) | |
| 40–59 | 604 | (43.8) | 217 | (42.6) | |
| ≥60 | 113 | (8.2) | 38 | (7.5) | |
| Year of transplant | 0.27 | ||||
| 1985–1994 | 365 | (26.5) | 150 | (29.5) | |
| 1995–2000 | 450 | (32.6) | 170 | (33.4) | |
| 2001–2005 | 564 | (40.9) | 189 | (37.1) | |
| Race/ethnicity | 0.85 | ||||
| White, non-Hispanic | 1,161 | (84.2) | 436 | (85.7) | |
| Black | 30 | (2.2) | 11 | (2.2) | |
| Hispanic | 64 | (4.6) | 23 | (4.5) | |
| Asian / Pacific Islander | 39 | (2.8) | 9 | (1.8) | |
| Other | 19 | (1.4) | 8 | (1.6) | |
| Unknown | 66 | (4.8) | 22 | (4.3) | |
| Underlying diagnosis | 0.63 | ||||
| Acute leukemia, myelodysplastic syndrome | 443 | (32.1) | 184 | (36.1) | |
| Chronic leukemia | 206 | (14.9) | 67 | (13.2) | |
| Lymphoma | 305 | (22.1) | 106 | (20.8) | |
| Multiple myeloma | 169 | (12.3) | 53 | (10.4) | |
| Breast cancer | 77 | (5.6) | 34 | (6.7) | |
| Neuroblastoma | 50 | (3.6) | 18 | (3.5) | |
| Other solid tumor | 35 | (2.5) | 9 | (1.8) | |
| Non-malignant blood disorder | 51 | (3.7) | 22 | (4.3) | |
| Immune/metabolic disease | 25 | (1.8) | 7 | (1.4) | |
| Multiple/systemic sclerosis | 18 | (1.3) | 9 | (1.8) | |
| Pre-transplant exposures† | |||||
| Alkylating agent | - | 277 | (54.5) | ||
| Anthracycline, mg/m2 | |||||
| None | - | 151 | (29.8) | ||
| <200 | - | 124 | (24.5) | ||
| 200–299 | - | 80 | (15.8) | ||
| ≥300 | - | 151 | (29.8) | ||
| Radiotherapy | |||||
| Brain | - | 18 | (3.5) | ||
| Neck | - | 35 | (6.9) | ||
| Spine | - | 24 | (4.7) | ||
| Chest | - | 53 | (10.4) | ||
| Abdomen/pelvis | - | 41 | (8.1) | ||
| Prior total body/lymphoid | - | 3 | (0.6) | ||
| Stem cell donor | 0.70 | ||||
| Autologous | 599 | (43.4) | 218 | (42.8) | |
| Related allogeneic | 491 | (35.6) | 191 | (37.5) | |
| Unrelated allogeneic | 289 | (21.0) | 100 | (19.6) | |
| Stem cell source‡ | 0.53 | ||||
| Marrow | 584 | (42.3) | 220 | (43.2) | |
| Peripheral blood | 819 | (59.4) | 297 | (58.3) | |
| Cord blood | 12 | (0.9) | 2 | (0.4) | |
| Transplant conditioning regimen§ | |||||
| No total body irradiation (TBI) | 736 | (53.4) | 260 | (51.1) | 0.54 |
| TBI, 1–9 Gy | 102 | (7.4) | 35 | (6.9) | |
| TBI, ≥10Gy | 541 | (39.2) | 214 | (42.0) | |
| Cyclophosphamide/TBI | 413 | (29.9) | 165 | (32.4) | 0.30 |
| Busulfan/cyclophosphamide | 263 | (19.1) | 84 | (16.5) | 0.20 |
| Chronic graft vs. host disease | 483 | (35.0) | 175 | (34.4) | 0.79 |
| Resolved at last follow-up†, ** | - | 113 | (22.2) | ||
| Post-transplant relapse | 359 | (26.0) | 146 | (28.7) | 0.25 |
| Relapse within 2 yrs of transplant | 217 | (15.7) | 86 | (16.9) | |
| Died, any cause** | 353 | (25.6) | 146 | (28.7) | 0.18 |
*
Proportions shown based on those without missing data.
†
Only determined for sub-cohort.
‡
Exceeds totals because some individuals had mixed products as part of single or tandem transplants.
§
Categories are not mutually exclusive.
**
As of December 31, 2008.